bullish
Ninlaro (Ixazomib) - Oral Proteasome Inhibitor
187 Views16 Dec 2016 16:05
Ninlaro (ixazomib, formerly MLN9708, Takeda) is the first and the only oral proteasome inhibitor, approved by USFDA (Nov’15) (three months ahead...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 13-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Okja: The Fight Between Netflix Vs. CJ CGV05 Jun 2017
- Ninlaro (Ixazomib) - Oral Proteasome Inhibitor16 Dec 2016
- Netflix & Amazon Expand in Korea – Not a Coincidence20 Jan 2016
- Thoughts on Amazon –What Does Its Valuation Tells Us?01 Dec 2015
x